The development of AKI stage 3, need for kidney replacement therapy (KRT), or death within the first seven days after randomization was evaluated in a secondary analysis of the trial [58]: patients with [TIMP-2]•[IGFBP7] levels >0.3 (ng/ml)2/1000 even without clinical evidence of AKI within the first 6 h were more than twice as likely to develop the endpoint compared with those who presented with normal concentrations of the biomarkers. The gene discussed is TIMP2; the disease is acute kidney injury.